Switch Lab PIs Joost Schymkowitz and Frederic Rousseau developed a strong IP portfolio consisting of six patents around the targeted protein aggregation approach that became the Pept-In™ technology. They partnered with the New Ventures Unit of the Flemish Institute for Biotechnology (VIB) to find investors, and Aelin Therapeutics was founded in 2017 to use the Pept-In™ technology to develop novel therapeutic agents against multi-drug resistant bacteria and undruggable cancer targets.
Profs. Rousseau and Schymkowitz are scientific founders of-, and scientific advisors to Aelin Therapuetics.
Aelin attracted 27.5 million Euros in venture capital from a group of investors that included two pharmaceutical companies (the largest start-up funding for a Belgian spin-off at the time). Aelin won a Lifestars Award in 2018, recognizing its critical role in the advancement of the life science sector.